

# ESMO PRECEPTORSHIP PROGRAMME GASTROESOPHAGEAL CANCER

Multidisciplinary management, standards of care  
and future perspectives

Lima, Peru  
9-10 April 2025

---

**CO-CHAIRS** Paola Montenegro, Peru  
Elizabeth Smyth, United Kingdom

**SPEAKERS** Andrés Cervantes, Spain  
Tania Fleitas, Spain  
Marcelo Garrido, Chile  
Florian Lordick, Germany  
Guillermo Mendez, Argentina  
Alejandro Nieponice, Argentina  
Juan Manuel O'Connor, Argentina  
Cristian Pacheco, Peru  
Erika Ruiz, Mexico

---

## LEARNING OBJECTIVES

- Understand best clinical practices in the multidisciplinary management of gastroesophageal cancer, both in the neoadjuvant and metastatic settings
- Comprehend the importance of pathology and histo-prognostic factors in the treatment of gastroesophageal cancers
- Learn how to manage patients after disease progression, addressing side effects of treatments and special situations
- Gain insights into the evolving field of biomarker-targeted therapy and immunotherapy for gastroesophageal cancer

---

## ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 9 April 2025

14:30-14:45 15'	Welcome and introduction	Chairs: Paola Montenegro, PE Elizabeth Smyth, UK
14:45-15:50 65'	<b>SESSION 1</b> Epidemiology/genetics	Chairs: Florian Lordick, DE Juan Manuel O'Connor, AR
15'	Epidemiology of gastroesophageal cancer in Latin America	Cristian Pacheco, PE
20'	Biology and biomarkers in gastroesophageal cancer	Tania Fleitas, ES
15'	Microbiota influence in gastroesophageal cancer	Erika Ruiz, MX
15'	Q&A	All
15:50-16:20	Coffee break	
16:20-17:50 90'	<b>SESSION 2</b> Operable gastroesophageal cancer	Chairs: Andrés Cervantes, ES Paola Montenegro, PE
20'	Gastroesophageal junction cancer Chemo vs Chemo radiotherapy	Juan Manuel O'Connor, AR
20'	Should immunotherapy be used in operable gastroesophageal adenocarcinoma?	Elizabeth Smyth, UK
20'	Surgery for gastric and gastroesophageal junction cancer, which surgery and when?	Alejandro Nieponice, AR
30'	Participants clinical case discussion (2x15')	Faculty
20:00	Networking Dinner	

## Thursday, 10 April 2025

10:00-11:10 70'	<b>SESSION 3</b> Treatment of advanced disease	Chairs: Tania Fleitas, ES Erika Ruiz, MX
20'	Chemotherapy for advanced gastric cancer; doublet and triplet, elderly patients	Florian Lordick, DE
20'	Second line and third line treatments	Paola Montenegro, PE
30'	Participants clinical case discussion (2x15')	Faculty
11:10-11:40	Coffee break	

<b>11:40-13:00</b> 80'	<b>SESSION 4</b> <b>Biomarker targeted therapy and immunotherapy</b>	<b>Chairs:</b> <b>Alejandro Nieponice, AR</b> <b>Elizabeth Smyth, UK</b>
20'	Sequencing HER2 directed therapy	Andrés Cervantes, ES
20'	Immunotherapy new challenges	Marcelo Garrido, CL
20'	Emerging therapies; claudin 18.2, FGFR2 etc	Tania Fleitas, ES
20'	Q&A	Faculty
<b>13:00-14:00</b>	<b>Lunch</b>	
<b>14:00-15:30</b> 90'	<b>SESSION 5</b> <b>Oligometastatic gastroesophageal cancer</b>	<b>Chairs:</b> <b>Andrés Cervantes, ES</b> <b>Erika Ruiz, MX</b>
40'	DEBATE: Patients with oligometastatic gastroesophageal cancer should be surgical candidates - YES - NO	Alejandro Nieponice, AR Guillermo Mendez, AR
30'	Participants clinical case discussion (2x15')	Faculty
20'	Q&A	All
<b>15:30-16:00</b>	<b>Coffee break</b>	
<b>16:00-17:00</b> 60'	<b>SESSION 6</b> <b>Challenging Clinical Situations</b>	<b>Chair:</b> <b>Marcelo Garrido, CL</b>
5'	Case Presentation Case of squamous cell cancer: To operate or not to operate?	Guillermo Mendez, AR
15'	Q&A	All
5'	Case Presentation Case of gastric cancer signet ring cells that requires neoadjuvant therapy	Paola Montenegro, PE
15'	Q&A	All
5'	Case Presentation Case of gastric cancer with neoadjuvant therapy operated without response	Florian Lordick, DE
15'	Q&A	All
<b>17:00-17:10</b> 10'	<b>Closing remarks</b>	
10'	Closing and final remarks	Paola Montenegro, PE Elizabeth Smyth, UK

**Note:** Each 15-minute slot for clinical case discussion includes 5' case presentation and 10' Q&A / panel discussion